Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity
Funding through Part B topline results depends on full and timely exercise of outstanding Series A and B warrants.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Inhibikase Therapeutics (Nasdaq: IKT) reported a third-quarter 2026 net loss of $20.5 million while advancing its Phase 3 IMPROVE-PAH trial.
The loss compared with $11.9 million a year earlier; loss per share narrowed to $0.10 from $0.13. Research and development expenses rose to $15.0 million from $7.6 million. Cash, cash equivalents and marketable securities totaled $193.3 million at September 30. July's sale of 25,000,000 shares to RA Capital raised $50 million gross; 18,030,000 shares were subsequently exchanged for pre-funded warrants.
By November, IMPROVE-PAH had approvals in 28 countries and 79 of 180 planned sites activated. Inhibikase plans an interim safety readout in the first half of 2027. It expects funding through Part B topline results, assuming full and timely exercise of outstanding Series A and B warrants. IKT-001 received FDA Orphan Drug Designation in July.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointJuly's RA Capital share sale raised $50 million in gross proceeds. 21% of market cap
- Moderate pointCash, cash equivalents and marketable securities totaled $193.3 million at September 30, 2026.
- Moderate pointIMPROVE-PAH secured 28 country approvals, with 79 of 180 planned sites activated by November 2026.
- Minor pointIKT-001 received FDA Orphan Drug Designation, providing potential development incentives and possible seven-year exclusivity upon approval.
- Minor point. Forward-looking: it has not happened yet and may not happen.Part A interim safety readout involving 50 patients is planned for the first half of 2027.
6 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Sotatercept combination nonclinical results are expected progressively, starting in first-quarter 2027.
- Minor pointRegulatory filings have begun to support combination therapy within Part B.
- Minor point. Forward-looking: it has not happened yet and may not happen.Nonclinical studies exploring pulmonary hypertension associated with heart failure expect results during 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Nonclinical studies exploring pulmonary hypertension associated with interstitial lung disease expect results late 2027 or early 2028.
- Minor pointThird-quarter other income increased to $1,761,723 from $838,093 a year earlier.
- Minor pointNine-month other income increased to $4,682,566 from $2,674,119 a year earlier.
Negative
- Major pointJuly financing issued 25,000,000 shares; 18,030,000 were subsequently exchanged for pre-funded warrants, retaining dilution exposure.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Expected funding through Part B topline results assumes full and timely Series A and B warrant exercise.
- Moderate pointThird-quarter net loss widened to $20.5 million from $11.9 million; per-share loss narrowed to $0.10 from $0.13.
- Moderate pointThird-quarter research and development expenses increased to $15.0 million from $7.6 million a year earlier.
- Moderate pointNine-month operating cash use increased to $41,855,564 from $20,270,491 a year earlier.
5 minor points
- Minor pointNine-month net loss widened to $56.4 million from $35.5 million; per-share loss narrowed to $0.31 from $0.40.
- Minor pointNine-month research and development expenses increased to $39.2 million from $23.4 million a year earlier.
- Minor pointThird-quarter selling, general and administrative expenses increased to $7.2 million from $5.6 million a year earlier.
- Minor pointNine-month selling, general and administrative expenses increased to $22.3 million from $16.8 million a year earlier.
- Minor pointNine-month securities issuance proceeds were reported net of $1.3 million in issuance costs.
News Explained
The additional quarter-end ownership detail is that on
Key Figures
- Cash and marketable securities
- $193.3 million
- As of September 30, 2026
- Net loss
- $20.5 million
- Quarter ended September 30, 2026
- Net loss
- $56.4 million
- Nine months ended September 30, 2026
- Country regulatory approvals
- 28 countries
- IMPROVE-PAH as of November 2026
- Activated clinical sites
- 79 of 180 planned sites
- IMPROVE-PAH as of November 2026
- Part A interim safety readout
- First half of 2027
- Planned readout; n=50
- Part A planned enrollment
- Approximately 140 patients
- IMPROVE-PAH; primary endpoint is change in PVR at Week 24
- Part B planned enrollment
- Approximately 346 patients
- IMPROVE-PAH; primary endpoint is change in 6MWD at Week 24
Previous Earnings Reports
-
Reported higher quarterly net loss alongside IMPROVE-PAH progress, including 26 country approvals and 43 sites.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pah medical
6mwd medical
orphan drug designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended September 30, 2026, and highlighted recent developments.
“During our third quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study, for which we have obtained 28 country regulatory approvals in the U.S. and E.U., with 79 clinical sites activated across a range of countries,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “We continue to expand our clinical footprint and look forward to additional country and site activations over the coming months. Supported by the
Recent Developments
- As of November 2026, regulatory approvals for the IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332) have been obtained in 28 countries globally; 79 of a planned 180 clinical sites have been activated.
- The global IMPROVE-PAH trial is a two-part adaptive Phase 3 study. Part A of IMPROVE-PAH is a double blind, placebo-controlled study in approximately 140 patients with a primary endpoint of change in Pulmonary Vascular Resistance (“PVR”) at Week 24. Part B of IMPROVE-PAH seamlessly begins following the enrollment of the last patient in Part A and adopts an identical format to Part A except the primary endpoint of Part B is change in 6-minute walk distance (“6MWD”) at Week 24 in approximately 346 patients.
- An interim safety readout for Part A of the Phase 3 IMPROVE-PAH study (n=50) is planned for the first half of 2027.
- The global IMPROVE-PAH trial is a two-part adaptive Phase 3 study. Part A of IMPROVE-PAH is a double blind, placebo-controlled study in approximately 140 patients with a primary endpoint of change in Pulmonary Vascular Resistance (“PVR”) at Week 24. Part B of IMPROVE-PAH seamlessly begins following the enrollment of the last patient in Part A and adopts an identical format to Part A except the primary endpoint of Part B is change in 6-minute walk distance (“6MWD”) at Week 24 in approximately 346 patients.
- In October 2026, the Company announced the appointment of Scott M. Wasserman, MD, to the Company’s Board of Directors. Dr. Wasserman is currently the Chief Medical Officer of Kailera Therapeutics, a clinical-stage company developing GLP-1-based therapeutics for obesity and related conditions. Dr. Wasserman is a cardiologist with more than two decades of experience in clinical development and company leadership.
- In July 2026, the Company sold 25,000,000 shares of the Company’s common stock to new shareholder RA Capital Management through its at-the-market (“ATM”) facility for gross proceeds of
$50 million . Subsequently, in July 2026, 18,030,000 of these shares of common stock were exchanged for pre-funded warrants to purchase shares of common stock. - In July 2026, the FDA’s Office of Orphan Products Development granted Orphan Drug Designation (“ODD”) for IKT-001. ODD provides potential development incentives, including eligibility for tax credits on qualified clinical trial costs, exemption from certain FDA user fees, and the potential for seven years of market exclusivity upon regulatory approval.
Nonclinical and Development Update
Over the last few months and extending into 2027, the Company has enhanced its focus on additional nonclinical activities that have the potential to broaden the scientific rationale for IKT-001 across the following themes:
- Sotatercept Combination: Building on previously published nonclinical evidence supporting the potential to provide PAH patients with additive hemodynamic improvements via the complementary combination of IKT-001 and an active signaling inhibitor, Inhibikase’s additional nonclinical studies are focused on deepening the mechanistic and translational rationale for combining IKT-001 with sotatercept with results expected progressively, starting in the first quarter of 2027. Additionally, the Company has begun regulatory filings to support combination therapy within Part B of the ongoing Phase 3 program.
- Group 2 Potential: Beyond the Company’s current single pivotal Phase 3 in Group 1 PAH patients, Inhibikase is undertaking various nonclinical activities to explore the potential of IKT-001 to improve myocardial fibrosis and diastolic function. These efforts will evaluate the potential of IKT-001 to address both pulmonary vascular remodeling and underlying cardiac dysfunction in HFpEF-associated pulmonary hypertension with results expected during 2027.
- Group 3 Potential: The Company is also evaluating whether IKT-001 has the potential to reduce pulmonary vascular resistance and vascular remodeling, improve right-heart function, and provide therapeutic benefit in PH-ILD (Group 3) nonclinical models. These studies will explore the potential of IKT-001 to reduce the abnormal remodeling of pulmonary arteries, as well as a possible direct antifibrotic effect, with results expected during late 2027 or early 2028.
Investor Conferences
Inhibikase is participating in the following upcoming investor conferences:
Jefferies Global Healthcare Conference
November 16–19, 2026
London, United Kingdom
Format: Fireside Chat with Mark Iwicki of Inhibikase and Dennis Ding, Jefferies Research
Date: Monday, November 16
Webcast: Click here
9th Annual Evercore Healthcare Conference
November 30–December 2, 2026
Coral Gables, Florida
Mr. Iwicki will participate in one-on-one investor meetings on Tuesday, December 1. Investors interested in scheduling a meeting should contact their Evercore representative.
Financial Results
Cash Position: As of September 30, 2026, cash, cash equivalents and marketable securities were
As of September 30, 2026, there were 140.3 million shares of common stock and 60.6 million pre-funded warrants outstanding.
Net Loss: Net loss for the quarter ended September 30, 2026, was
R&D Expenses: Research and development expenses were
SG&A Expenses: Selling, general and administrative expenses for the quarter ended September 30, 2026 were
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit,” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.
Social Media Disclaimer
Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the potential of IKT-001, including its potential to become a once-daily oral anti-proliferative treatment for PAH and its potential benefits to patients with PAH, the advancement of the Company’s global pivotal Phase 3 clinical study of IKT-001 in PAH, including the timing, design, conduct and anticipated interim safety readout of the IMPROVE-PAH study and related regulatory submissions, the Company’s ability to obtain additional regulatory approvals for the IMPROVE-PAH study, including any approvals needed to evaluate combination therapy in Part B, the Company’s beliefs regarding the potential advantages of the Phase 3 clinical study of IKT-001, the Company’s nonclinical studies of IKT-001 in combination with sotatercept and its potential use in Group 2 and Group 3 pulmonary hypertension, including the expected timing and results of those studies and potential therapeutic benefits, the potential benefits of Orphan Drug Designation, the Company’s expectations regarding its cash runway and ability to fund operations through the topline data readout from Part B of IMPROVE-PAH, expectations regarding the exercise of the outstanding Series A and B Warrants, or future events or conditions. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contacts:
Investor Relations:
Michael Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
---tables to follow---
| Inhibikase Therapeutics, Inc. Condensed Consolidated Balance Sheets (Unaudited) | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | (Note 1) | |||||||
| Assets | | |||||||
| Current assets: | | |||||||
| Cash and cash equivalents | $ | 51,701,197 | $ | 139,220,208 | ||||
| Marketable securities | 141,619,768 | 39,543,820 | ||||||
| Prepaid research and development | 3,998,159 | 1,001,993 | ||||||
| Prepaid expenses and other current assets | 1,412,941 | 343,374 | ||||||
| Total current assets | 198,732,065 | 180,109,395 | ||||||
| Prepaid research and development, noncurrent | 2,780,307 | 1,000,000 | ||||||
| Other assets | 239,577 | 95,121 | ||||||
| Total assets | $ | 201,751,949 | $ | 181,204,516 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 947,993 | $ | 1,158,054 | ||||
| Accrued expenses and other current liabilities (see Note 6) | 12,008,758 | 4,081,282 | ||||||
| Contingent consideration liability | — | 3,061,501 | ||||||
| Total current liabilities | 12,956,751 | 8,300,837 | ||||||
| Total liabilities | 12,956,751 | 8,300,837 | ||||||
| Commitments and contingencies (see Note 13) | ||||||||
| Stockholders’ equity: | | | ||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 140,270 | 131,691 | ||||||
| Additional paid-in capital | 387,883,494 | 315,429,986 | ||||||
| Accumulated other comprehensive (loss) income | (109,361 | ) | 21,802 | |||||
| Accumulated deficit | (199,119,205 | ) | (142,679,800 | ) | ||||
| Total stockholders' equity | 188,795,198 | 172,903,679 | ||||||
| Total liabilities and stockholders’ equity | $ | 201,751,949 | $ | 181,204,516 | ||||
| Inhibikase Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Costs and expenses: | ||||||||||||||||
| Research and development | $ | 14,999,866 | $ | 7,649,697 | $ | 39,232,480 | $ | 23,434,243 | ||||||||
| Selling, general and administrative | 7,229,191 | 5,611,503 | 22,262,845 | 16,780,525 | ||||||||||||
| Change in fair value contingent consideration | — | (492,827 | ) | (373,354 | ) | (2,016,111 | ) | |||||||||
| Total costs and expenses | 22,229,057 | 12,768,373 | 61,121,971 | 38,198,657 | ||||||||||||
| Loss from operations | (22,229,057 | ) | (12,768,373 | ) | (61,121,971 | ) | (38,198,657 | ) | ||||||||
| Other income | 1,761,723 | 838,093 | 4,682,566 | 2,674,119 | ||||||||||||
| Net loss | (20,467,334 | ) | (11,930,280 | ) | (56,439,405 | ) | (35,524,538 | ) | ||||||||
| Other comprehensive loss | ||||||||||||||||
| Unrealized (loss) gain on marketable securities | (36,607 | ) | (1,245 | ) | (131,163 | ) | 33,059 | |||||||||
| Comprehensive loss | $ | (20,503,941 | ) | $ | (11,931,525 | ) | $ | (56,570,568 | ) | $ | (35,491,479 | ) | ||||
| Net loss per share – basic and diluted | $ | (0.10 | ) | $ | (0.13 | ) | $ | (0.31 | ) | $ | (0.40 | ) | ||||
| Weighted-average number of shares – basic and diluted | 196,938,811 | 90,050,973 | 181,362,655 | 89,867,805 | ||||||||||||
| Inhibikase Therapeutics, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) | ||||||||
| Nine months ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (56,439,405 | ) | $ | (35,524,538 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | — | 60,499 | ||||||
| Stock-based compensation expense | 16,433,584 | 10,776,144 | ||||||
| Write-off of in-process research and development | — | 7,357,294 | ||||||
| Change in fair value contingent consideration | (373,354 | ) | (2,016,111 | ) | ||||
| Non-cash accretion on marketable securities | (3,203,308 | ) | (570,503 | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Operating lease right-of-use assets | — | 101,437 | ||||||
| Prepaid expenses and other current assets | (1,069,567 | ) | 257,321 | |||||
| Current and non-current prepaid research and development | (4,776,473 | ) | (1,129,258 | ) | ||||
| Other assets | (144,456 | ) | (57,913 | ) | ||||
| Accounts payable | (210,061 | ) | (390,699 | ) | ||||
| Operating lease liabilities | — | (110,517 | ) | |||||
| Accrued expenses and other current liabilities | 7,927,476 | 976,353 | ||||||
| Net cash used in operating activities | (41,855,564 | ) | (20,270,491 | ) | ||||
| Cash flows from investing activities | ||||||||
| Purchases of equipment and improvements | — | (13,399 | ) | |||||
| Purchases of investments - marketable securities | (221,303,803 | ) | (38,996,000 | ) | ||||
| Maturities of investments - marketable securities | 122,300,000 | 41,600,000 | ||||||
| Acquired in-process research and development | — | (438,624 | ) | |||||
| Net cash provided by (used in) investing activities | (99,003,803 | ) | 2,151,977 | |||||
| Cash flows from financing activities | ||||||||
| Deferred offering costs | — | (385,062 | ) | |||||
| Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs of | 52,011,159 | 150 | ||||||
| Proceeds from the exercise of Series A-1 warrants | 1,000,100 | — | ||||||
| Exchange of common stock for pre-funded warrants | (18,030 | ) | — | |||||
| Issuance of common stock from exercise of options | 347,127 | 282,553 | ||||||
| Net cash provided by (used in) financing activities | 53,340,356 | (102,359 | ) | |||||
| Net decrease in cash and cash equivalents | (87,519,011 | ) | (18,220,873 | ) | ||||
| Cash and cash equivalents at beginning of period | 139,220,208 | 56,490,579 | ||||||
| Cash and cash equivalents at end of period | $ | 51,701,197 | $ | 38,269,706 | ||||
| Non-cash investing and financing activities | ||||||||
| Contingent consideration | $ | — | $ | 2,419,332 | ||||
| Share forfeited and contingent consideration reclassified to additional paid-in capital | $ | 2,688,147 | $ | — | ||||
| CorHepta transaction costs | $ | — | $ | 175,000 | ||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Inhibikase Therapeutics' third-quarter 2026 financial results?
Inhibikase reported a $20.5 million net loss, or $0.10 per share, compared with $11.9 million, or $0.13 per share, a year earlier. Research and development expenses were $15.0 million, while selling, general and administrative expenses were $7.2 million.
When does Inhibikase expect the IMPROVE-PAH interim safety readout?
Inhibikase plans an interim safety readout for 50 patients in Part A in the first half of 2027. By November 2026, the Phase 3 study had regulatory approvals in 28 countries and 79 of a planned 180 clinical sites activated.
What does Inhibikase's Phase 3 IMPROVE-PAH trial measure?
Part A measures change in pulmonary vascular resistance, the resistance blood encounters in lung vessels, at Week 24 in approximately 140 patients. Part B measures change in six-minute walking distance at Week 24 in approximately 346 patients. Both parts are blinded and placebo-controlled; Part B begins after the last patient enrolls in Part A.
What incentives could Inhibikase receive from IKT-001's Orphan Drug Designation?
The designation provides potential eligibility for tax credits on qualified clinical trial costs, exemption from certain FDA user fees, and potential seven-year market exclusivity upon regulatory approval. The FDA's Office of Orphan Products Development granted the designation in July 2026.